Verition Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $196K | Sell |
21,896
-47,964
| -69% | -$430K | ﹤0.01% | 2633 |
|
|
2025
Q1 | $524K | Buy |
69,860
+15,414
| +28% | +$116K | ﹤0.01% | 1968 |
|
|
2024
Q4 | $409K | Buy |
54,446
+14,926
| +38% | +$112K | ﹤0.01% | 1982 |
|
|
2024
Q3 | $300K | Sell |
39,520
-102,839
| -72% | -$782K | ﹤0.01% | 1972 |
|
|
2024
Q2 | $880K | Buy |
+142,359
| New | +$880K | ﹤0.01% | 1214 |
|
|
2024
Q1 | – | Sell |
-31,510
| Closed | -$189K | – | 2156 |
|
|
2023
Q4 | $189K | Sell |
31,510
-17,470
| -36% | -$105K | ﹤0.01% | 1614 |
|
|
2023
Q3 | $347K | Buy |
48,980
+18,300
| +60% | +$130K | ﹤0.01% | 1345 |
|
|
2023
Q2 | $216K | Buy |
30,680
+8,400
| +38% | +$59.1K | ﹤0.01% | 1537 |
|
|
2023
Q1 | $186K | Buy |
+22,280
| New | +$186K | ﹤0.01% | 1622 |
|
|
2022
Q2 | – | Sell |
-15,513
| Closed | -$252K | – | 2210 |
|
|
2022
Q1 | $252K | Buy |
+15,513
| New | +$252K | ﹤0.01% | 1479 |
|
|
2021
Q3 | – | Sell |
-14,634
| Closed | -$231K | – | 1649 |
|
|
2021
Q2 | $231K | Buy |
+14,634
| New | +$231K | ﹤0.01% | 1357 |
|
|
2020
Q4 | – | Sell |
-541,839
| Closed | -$1.86M | – | 988 |
|
|
2020
Q3 | $1.86M | Buy |
+541,839
| New | +$1.86M | 0.04% | 219 |
|